Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Insulin Glulisine U300 vs U100 in T1DM
NCT02910518Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glulisine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum observed insulin concentration at 10 hours and Area under the concentration time curve at 10 hours. Started Feb 2017; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02910518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910518.